Genmab A/S (GMAB) to Release Quarterly Earnings on Thursday

Genmab A/S (NASDAQ:GMAB) is set to announce its earnings results before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of $0.16 per share for the quarter. Genmab A/S has set its FY 2024 guidance at EPS.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Wednesday, February 14th. The company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.02. The firm had revenue of $675.29 million during the quarter, compared to the consensus estimate of $678.14 million. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. On average, analysts expect Genmab A/S to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Genmab A/S Price Performance

NASDAQ GMAB opened at $28.47 on Thursday. The company has a market cap of $18.83 billion, a P/E ratio of 29.66, a P/E/G ratio of 2.08 and a beta of 0.99. The stock has a 50-day moving average of $29.46 and a two-hundred day moving average of $30.14. Genmab A/S has a 1-year low of $26.32 and a 1-year high of $42.72.

Analysts Set New Price Targets

GMAB has been the subject of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research report on Thursday, April 4th. BMO Capital Markets raised Genmab A/S from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $46.00 to $48.00 in a research report on Friday, February 23rd. Morgan Stanley reaffirmed an “underweight” rating on shares of Genmab A/S in a research report on Tuesday, March 26th. Citigroup downgraded Genmab A/S from a “neutral” rating to a “sell” rating in a research report on Monday, January 22nd. Finally, Truist Financial reaffirmed a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research report on Tuesday, March 26th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $48.50.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.